Publications by authors named "E Tampouratzi"
Article Synopsis
- - The BrIDGE study examined the real-world effectiveness of brodalumab in treating moderate-to-severe plaque psoriasis in Greece, focusing on the percentage of patients achieving complete clearance (PASI100) over 24 weeks and beyond.
- - Results showed that 42% of patients reached PASI100 at Week 24, with this number increasing to 65% by Week 104, while significant improvements were noted in other assessment scores (PASI75, PASI90, and sPGA).
- - Additionally, patients reported improved quality of life, with average scores on the Dermatology Life Quality Index (DLQI) decreasing significantly over the study period, indicating better overall well-being as a result of brodalumab treatment
Article Synopsis
- Psoriasis is a chronic condition, and switching treatment options is common for patients who don't respond well to initial therapies, particularly for those with more severe disease.
- Patients who switch biologics may develop anti-drug antibodies, which could reduce the effectiveness of future treatments.
- An observational study of five patients with severe plaque psoriasis showed that after switching from brodalumab to adalimumab and then back to brodalumab, patients experienced a significant return of efficacy, improving both skin and joint symptoms.